In his new role, Gupta will lead Merck’s global information technology and digital strategy, overseeing artificial intelligence, enterprise data, digital platforms, cybersecurity, and technology innovation.
Merck has appointed Gaurav Gupta as Executive Vice President and Chief Information & Digital Officer (CIDO). He joined the company in July 2026 and will officially assume the role on September 1, 2026, succeeding Dave Williams, who is retiring after leading the company’s digital transformation.
In his new role, Gupta will lead Merck’s global information technology and digital strategy, overseeing artificial intelligence, enterprise data, digital platforms, cybersecurity, and technology innovation. He will also support the company’s digital transformation initiatives aimed at enabling scientific innovation, operational excellence, and business growth.
Before joining Merck, Gupta spent more than 27 years at Ernst & Young (EY), including over 16 years as a Partner/Principal in the firm’s Life Sciences Digital practice in New York. As a Senior Partner, he led global teams responsible for AI-powered digital transformation programs across the pharmaceutical and life sciences value chain.
Earlier at EY, he served as Senior Manager, where he worked on enterprise technology consulting, digital transformation, business strategy, information systems, and large-scale technology implementation projects for global clients.
Prior to EY, Gupta worked as an Assistant Manager at Sundaram Finance, where he gained experience in financial services, business operations, and technology-enabled business transformation.
According to the company, Gupta has built expertise in digital transformation, artificial intelligence, enterprise technology, data strategy, business modernization, information systems, and technology innovation across the global healthcare and life sciences sector.
Gupta holds a Master of Business Administration (MBA) in Finance and Management Information Systems (MIS) from Ohio University.
Merck, known as MSD outside the United States and Canada, develops medicines and vaccines for human and animal health and continues to invest in scientific innovation, digital transformation, and technology across its global operations.
Stay tuned for more such updates on Digital Health News